A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a ...

A mother gives her baby immunity even before birth. Vaccines during pregnancy protect both, boosting the baby's defense ...

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...

Researchers at the University of Colorado Anschutz Medical Campus have uncovered a critical, previously underappreciated role ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

According to WHO, 254 million people globally were estimated to have HBV in 2022, but only approximately 10% had been ...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blow with the recent closure of the CDC’s ...

BriaCell (BCTX) Therapeutics announces that BriaPro is developing novel, high affinity antibodies to B7-H3, a key player in cancer progression, using molecular modeling techniques. BriaPro has ...

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly expressed on the cell surfaces of both tumor and immune cells, B7-H3 is a promising anti-cancer ...

HBV=hepatitis B virus. HBVDR=HBV drug resistance. i-GAP=integrated Global Action Plan. RAM=resistance-associated mutation(s). ∗Newly proposed definitions, based on those used in the HIV drug ...

Merida’s therapeutics also aim to deplete the B cells responsible for producing the harmful antibodies. Merida’s lead programme will focus on Graves’ disease, an autoimmune condition that causes the ...